Abgenix has a one of a kind strategy for producing antibodies valuable in treating various infections, including disease. In mid 2000, the organization's disease has performed exceptionally well in creature testing and is moving to early stage human testing. Abgenix must choose whether to offer the item improvement program to an extensive pharmaceutical organization or to go into a joint dare to push the item ahead.
Subject | Not Selected |
Length | Not Selected |
Deadline | Not Selected |
Estimated Submission On | |
Total | 0 |